Navigation Links
Qteros Management to Present at Upcoming Conferences in May
Date:4/28/2011

MARLBOROUGH, Mass., April 28, 2011 /PRNewswire/ -- Qteros, Inc., the developer of a unique and highly efficient Consolidated Bioprocessing (CBP) platform for the lowest-cost production of cellulosic ethanol, today announced its plans to present at various industry conferences throughout the month of May.

Kevin A. Gray, Ph.D., Senior Vice President and Chief Scientific Officer for Qteros, will deliver an oral presentation at the 33rd Symposium on Biotechnology for Fuels and Chemicals being held at the Sheraton Seattle, Washington. His presentation, "Technology Development and Scale-up of the Production of Lignocellulosic Ethanol using the Microbe Clostridium phytofermentans" will be presented during Session 9: Biofuels and Biorefinery Economics and Sustainability on Tuesday, May 3, 2011 at 1:00pm PDT.

Mick Sawka, Qteros' Senior Vice President of Commercial Development and Engineering, will also present on May 3, 2011 at Thomson Reuters' Open Innovation Seminar. The presentation is scheduled for 8:00am EDT and will be held at Thomson Reuters' offices in Boston, MA.

Dr. Gray will participate in the 2011 World Congress on Industrial Biotechnology & Bioprocessing in Toronto, Ontario, Canada. On Monday, May 9, 2011 at 8:45am EDT, Dr. Gray will deliver a presentation entitled, "Plant Cell Wall Degrading Micro-Organisms as Biocatalysts for Biofuels and Bio-Chemicals Production."  On Tuesday, May 10, 2011, at 9:00am EDT, Dr. Gray will moderate a panel entitled, "Engineering Low Cost Feedstocks to Value-Add Bio-chemicals." He will deliver a presentation during this panel discussion entitled, "Clostridium phytofermentans as an Inexpensive Sugar Platform for Biochemicals."

About Qteros, Inc.
Qteros' mission is to accelerate the global commercialization of large-scale, lowest-cost cellulosic ethanol production. Qteros has teamed with a core group of world-class strategic partners that complement and leverage our advanced microbiology and process engineering expertise. Working closely with its strategic partners, Qteros expects to rapidly scale its highly efficient, lowest-cost Consolidated Bioprocessing (CBP) platform for converting non-food biomass into biofuels. Qteros is funded by leading investors in the alternative energy industry including, among others, Venrock Associates, Battery Ventures, BP AE Ventures, Soros Fund Management LLC, and Valero Energy Corporation. For more information, please visit www.qteros.com.

CONTACT:
Susan Hager
VP Corporate Communications & Government Affairs
shager@qteros.com
(508) 251-6339


'/>"/>
SOURCE Qteros, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Qteros Management to Present at Alternative Energy Investment Banking Conferences
2. Qteros Management to Present at Notable Alternative Energy Conferences in February
3. Qteros and Praj Industries Announce Broad Strategic Partnership to Accelerate Global Commercialization of Cellulosic Ethanol
4. Qteros and UMass Amherst Announce the Issuance of a U.S. Patent for Production of Ethanol From a Unique Microorganism, the Q Microbe(TM)
5. Biofuels Technology Leader Qteros Names Mick Sawka Vice President, Business Development
6. Biofuels Technology Leader Qteros Names Industry Veteran John McCarthy President and Chief Executive Officer
7. Cellulosic Biofuels Leader Qteros Adds Key Positions
8. Qteros Employees Planting Special Trees in Celebration of International Day of Climate Action, October 24, 2009
9. Conflict of Interest Management System Selected by Henry Ford Health System
10. Best Practices, LLC Showcases Its Expertise in Customer Relationship Management
11. SPX Announces Acquisition of B.W. Murdoch Ltd, Broadening Process Engineering and Project Management Capabilities in New Zealand and the Asia Pacific Region
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... with the addition of its newest module, US Hemostats & Sealants. , SmartTRAK’s ... hemostats, absorbable hemostats, fibrin sealants, synthetic sealants and biologic sealants used in surgical ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... any gene in its endogenous context, enabling overexpression experiments and avoiding the use ... with small RNA guides is transformative for performing systematic gain-of-function studies. , ...
(Date:10/11/2017)... -- VMS BioMarketing, a leading provider of patient support solutions, has ... (CNE) network, which will launch this week. The VMS CNEs ... professionals to enhance the patient care experience by delivering peer-to-peer ... care professionals to help women who have been diagnosed and ... ...
(Date:10/11/2017)... Bay, Florida (PRWEB) , ... October 11, 2017 ... ... and Drug Administration (FDA) has granted orphan drug designation to SBT-100, its novel ... (sdAb) for the treatment of osteosarcoma. SBT-100 is able to cross the cell ...
Breaking Biology Technology:
(Date:4/5/2017)... 2017 KEY FINDINGS The global ... a CAGR of 25.76% during the forecast period of ... factor for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is ... geography. The stem cell market of the product is ...
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
(Date:3/30/2017)... 2017 The research team of The Hong ... fingerprint identification by adopting ground breaking 3D fingerprint minutiae recovery and ... speed and accuracy for use in identification, crime investigation, immigration control, ... ... A research team led ...
Breaking Biology News(10 mins):